Astrocyte Biomarkers in Alzheimer's DiseaseCitation formats

  • External authors:
  • Pedro Rosa-Neto
  • Luc Pellerin
  • Agneta Nordberg
  • Eduardo R Zimmer

Standard

Astrocyte Biomarkers in Alzheimer's Disease. / Carter, Stephen F; Herholz, Karl; Rosa-Neto, Pedro; Pellerin, Luc; Nordberg, Agneta; Zimmer, Eduardo R.

In: Trends in molecular medicine, Vol. 25, No. 2, 02.2019, p. 77-95.

Research output: Contribution to journalReview articlepeer-review

Harvard

Carter, SF, Herholz, K, Rosa-Neto, P, Pellerin, L, Nordberg, A & Zimmer, ER 2019, 'Astrocyte Biomarkers in Alzheimer's Disease', Trends in molecular medicine, vol. 25, no. 2, pp. 77-95. https://doi.org/10.1016/j.molmed.2018.11.006

APA

Carter, S. F., Herholz, K., Rosa-Neto, P., Pellerin, L., Nordberg, A., & Zimmer, E. R. (2019). Astrocyte Biomarkers in Alzheimer's Disease. Trends in molecular medicine, 25(2), 77-95. https://doi.org/10.1016/j.molmed.2018.11.006

Vancouver

Carter SF, Herholz K, Rosa-Neto P, Pellerin L, Nordberg A, Zimmer ER. Astrocyte Biomarkers in Alzheimer's Disease. Trends in molecular medicine. 2019 Feb;25(2):77-95. https://doi.org/10.1016/j.molmed.2018.11.006

Author

Carter, Stephen F ; Herholz, Karl ; Rosa-Neto, Pedro ; Pellerin, Luc ; Nordberg, Agneta ; Zimmer, Eduardo R. / Astrocyte Biomarkers in Alzheimer's Disease. In: Trends in molecular medicine. 2019 ; Vol. 25, No. 2. pp. 77-95.

Bibtex

@article{b1e3e1f5e41d4cec9fbf386ce084fb64,
title = "Astrocyte Biomarkers in Alzheimer's Disease",
abstract = "Astrocytic contributions to Alzheimer's disease (AD) progression were, until recently, largely overlooked. Astrocytes are integral to normal brain function and astrocyte reactivity is an early feature of AD, potentially providing a promising target for preclinical diagnosis and treatment. Several in vivo AD biomarkers already exist, but presently there is a paucity of specific and sensitive in vivo astrocyte biomarkers that can accurately measure preclinical AD. Measuring monoamine oxidase-B with neuroimaging and glial fibrillary acidic protein from bodily fluids are biomarkers that are currently available. Developing novel, more specific, and sensitive astrocyte biomarkers will make it possible to pharmaceutically target chemical pathways that preserve beneficial astrocytic functions in response to AD pathology. This review discusses astrocyte biomarkers in the context of AD.",
author = "Carter, {Stephen F} and Karl Herholz and Pedro Rosa-Neto and Luc Pellerin and Agneta Nordberg and Zimmer, {Eduardo R}",
note = "Copyright {\textcopyright} 2018 Elsevier Ltd. All rights reserved.",
year = "2019",
month = feb,
doi = "10.1016/j.molmed.2018.11.006",
language = "English",
volume = "25",
pages = "77--95",
journal = "Trends in molecular medicine",
issn = "1471-4914",
publisher = "Elsevier BV",
number = "2",

}

RIS

TY - JOUR

T1 - Astrocyte Biomarkers in Alzheimer's Disease

AU - Carter, Stephen F

AU - Herholz, Karl

AU - Rosa-Neto, Pedro

AU - Pellerin, Luc

AU - Nordberg, Agneta

AU - Zimmer, Eduardo R

N1 - Copyright © 2018 Elsevier Ltd. All rights reserved.

PY - 2019/2

Y1 - 2019/2

N2 - Astrocytic contributions to Alzheimer's disease (AD) progression were, until recently, largely overlooked. Astrocytes are integral to normal brain function and astrocyte reactivity is an early feature of AD, potentially providing a promising target for preclinical diagnosis and treatment. Several in vivo AD biomarkers already exist, but presently there is a paucity of specific and sensitive in vivo astrocyte biomarkers that can accurately measure preclinical AD. Measuring monoamine oxidase-B with neuroimaging and glial fibrillary acidic protein from bodily fluids are biomarkers that are currently available. Developing novel, more specific, and sensitive astrocyte biomarkers will make it possible to pharmaceutically target chemical pathways that preserve beneficial astrocytic functions in response to AD pathology. This review discusses astrocyte biomarkers in the context of AD.

AB - Astrocytic contributions to Alzheimer's disease (AD) progression were, until recently, largely overlooked. Astrocytes are integral to normal brain function and astrocyte reactivity is an early feature of AD, potentially providing a promising target for preclinical diagnosis and treatment. Several in vivo AD biomarkers already exist, but presently there is a paucity of specific and sensitive in vivo astrocyte biomarkers that can accurately measure preclinical AD. Measuring monoamine oxidase-B with neuroimaging and glial fibrillary acidic protein from bodily fluids are biomarkers that are currently available. Developing novel, more specific, and sensitive astrocyte biomarkers will make it possible to pharmaceutically target chemical pathways that preserve beneficial astrocytic functions in response to AD pathology. This review discusses astrocyte biomarkers in the context of AD.

U2 - 10.1016/j.molmed.2018.11.006

DO - 10.1016/j.molmed.2018.11.006

M3 - Review article

C2 - 30611668

VL - 25

SP - 77

EP - 95

JO - Trends in molecular medicine

JF - Trends in molecular medicine

SN - 1471-4914

IS - 2

ER -